
Joan D. Beckman
@jd_beckman
Heme physician-scientist. Grew up in ND. Lois & Richard King Assistant Professor at University of Minnesota. #bison #gophers #cats. All opinions are my own.
ID: 2906541911
05-12-2014 16:41:01
4,4K Tweet
2,2K Followers
4,4K Following

We must press forward at all times... Now online for @BloodJournal "Sickle Cell Trait Does Not Cause "Sickle Cell Crisis" Leading to Exertion-Related Death: A Systematic Review" Roger Mitchell Jr MD Shematologist, MD Pat McGann, MD Rakhi Naik, MD MHS ashpublications.org/blood/article/…

Fun watching my peers from Masonic Cancer Center, University of Minnesota UMN H.O.T. Division UMN Medical School M Health Fairview play bball Minnesota Men's Basketball —






🚨Faculty Highlight🚨 Dr. Alexa Weingarden (Alexa Weingarden MD PhD) joined GI & Hepatology Division - University of Minnesota this summer! She studies how the immune system interacts with gut microbes to drive celiac disease. She will present findings from her work on food allergy in a plenary session at #DDW2025! 👏


The RENOVE trial found that while low-dose DOACs did not meet non-inferiority for preventing recurrent VTE, it showed a better risk-benefit ratio, with less clinically relevant bleeding. Dose reduction may be a good option for many patients! thelancet.com/journals/lance… Francis Couturaud


Grateful to the support of so many mentors and peers and proud to work with UMN H.O.T. Division Masonic Cancer Center, University of Minnesota UMN Medical School University of Minnesota UMN Biomedical Eng Lillehei Heart Institute

Despite their best intentions, cancer doctors don’t always fully appreciate how much time—and life—a person spends being treated for cancer, says Dr. Arjun Gupta from UMN Medicine & M Health Fairview. Read more about “time toxicity” in cancer treatment: bit.ly/3EvcT2q.



Ropeginterferon Alfa-2b Demonstrates Superior Efficacy & Safety to Anagrelide as 2L for ET - honored to have shared this yesterday during #ASCO25 Atrium Health Wake Forest Baptist Comprehensive Cancer Center Levine Cancer PharmaEssentia dailynews.ascopubs.org/do/ropeginterf…

Hot off the press! COBBRA trial showed that apixaban is associated with >50% reduced risk of clinically-relevant bleeding symptoms for acute VTE treatment. This can be practice changing! Lana Castellucci Marc Rodger CanVECTOR Network


